Keeping Track: US FDA Approves Pfizer’s Vyndaqel, Jacobus’ Ruzurgi, But Nixes Acacia’s Barhemsys Again

The latest drug development news and highlights from our US FDA Performance Tracker.

Keeping Track Feature image

Here's your US drug review news for week in brief: The Food and Drug Administration issued one long-awaited approval – for Pfizer Inc.’s tafamidis products Vyndaqel and Vyndamax – and one under-the-radar application, for Ruzurgi, an amifampridine product from Jacobus Pharmaceutical Company. Acacia Pharma Ltd. was not so lucky, receiving a second complete response letter for the anti-emetic Barhemsys.

Submissions clustered around new formulations and combinations, thanks to RedHill Biopharma Ltd.’s three-drug combo for Helicobacter pylori infection,

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

EU Biosimilar Filings, Opinions And Approvals

 
• By 

<p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

Stealth’s Elamipretide: Efficacy In Barth Syndrome Not Shown, US FDA Says

 
• By 

Cardiovascular and Renal Drugs Advisory Committee will consider whether open-label extension data from a randomized trial that failed its primary endpoint, along with a historical control comparison, are enough to support approval in the ultra-rare disease.

New EU Approvals

<p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Pink Sheet

Test FDA Voucher Program Approvals Will Come From Product Centers, But Ambiguity Lingers

 
• By 

It is unclear in a revised staff manual guide whether Commissioner's National Priority Voucher program approval “recommendations” from the drug and biologic center directors will be advisory or decisional, experts told the Pink Sheet.

COVID Vaccines: US FDA Changes Course, Wants New Formulas To Target KP.2 Subvariant ‘If Feasible’

 
• By 

Revised recommendation is based on most recent data on circulating strains in US, where KP.3 is now dominant. Novavax sticks with plans targeting the JN.1 ‘parent strain.’

Nancy Tests New Podcast Template

 

Pink Sheet reporter and editors discuss the US FDA’s changes to the COVID-19 vaccine indication and its revocation of the vaccine emergency use authorizations, as well as new vaccine coverage and reimbursement questions.